Announcement

Collapse
No announcement yet.

ECTRIMS2021 – Real-world Data Support Mavenclad Benefits in Relapsing MS

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    ECTRIMS2021 – Real-world Data Support Mavenclad Benefits in Relapsing MS

    ECTRIMS2021 – Real-world Data Support Mavenclad Benefits in Relapsing MS

    Mavenclad (cladribine) improves life quality for people with relapsing multiple sclerosis starting in the first year of treatment, and continues to slow disability progression a decade after its last treatment course, real-world data show.

    These findings were presented in two Merck KGaA-funded posters at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), running virtually through Oct. 15. Merck, known as EMD Serono in North America, is the developer of Mavenclad.

    “Those living with MS know the effect of a treatment goes beyond what is shown in MRIs or in bloodwork,” and many “express that the impact on physical and mental well-being is just as important,” Jeannette Lechner-Scott, PhD, senior staff specialist in the department of neurology and a conjoint professor at the University of Newcastle, in Australia, said in a press release.

    “The quality-of-life outcomes from the CLARIFY-MS study support that Mavenclad positively impacts these measures early in the treatment course,” Lechner-Scott added.

    Full article:

    #ECTRIMS2021 – Real-world Data Support Mavenclad for Relapsing MS (multiplesclerosisnewstoday.com)





    PPMS for 26 years (dx 1998)
    ~ Worrying will not take away tomorrow's troubles ~ But it will take away today's peace. ~
Working...
X